198 related articles for article (PubMed ID: 6814139)
1. Plasma progesterone levels during long-term treatment with levonorgestrel silastic implants.
Croxatto HB; Diaz S; Pavez M; Miranda P; Brandeis A
Acta Endocrinol (Copenh); 1982 Oct; 101(2):307-11. PubMed ID: 6814139
[TBL] [Abstract][Full Text] [Related]
2. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
3. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
Brache V; Alvarez-Sanchez F; Faundes A; Tejada AS; Cochon L
Contraception; 1990 Feb; 41(2):169-77. PubMed ID: 2107058
[TBL] [Abstract][Full Text] [Related]
4. Estradiol plasma levels during long-term treatment with Norplant subdermal implants.
Croxatto HB; Díaz S; Pavez M; Brandeis A
Contraception; 1988 Oct; 38(4):465-75. PubMed ID: 3145171
[TBL] [Abstract][Full Text] [Related]
5. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles.
Landgren BM; Diczfalusy E
Contraception; 1984 May; 29(5):437-46. PubMed ID: 6430642
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
[TBL] [Abstract][Full Text] [Related]
7. Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term Norplant use.
Alvarez F; Brache V; Tejada AS; Faúndes A
Contraception; 1986 Feb; 33(2):111-9. PubMed ID: 3084166
[TBL] [Abstract][Full Text] [Related]
8. Plasma levonorgestrel and progesterone levels in women treated with silastic covered rods containing levonorgestrel.
Croxatto HB; Díaz S; Brandeis A; Pavez M; Johansson ED
Contraception; 1985 Jun; 31(6):643-54. PubMed ID: 3930143
[TBL] [Abstract][Full Text] [Related]
9. Norplant implants: the mechanism of contraceptive action.
Segal SJ; Alvarez-Sanchez F; Brache V; Faundes A; Vilja P; Tuohimaa P
Fertil Steril; 1991 Aug; 56(2):273-7. PubMed ID: 1906407
[TBL] [Abstract][Full Text] [Related]
10. Phase I comparative clinical trial with subdermal implants--bioabsorbable levonorgestrel or norethisterone pellet fused with cholesterol.
Joshi UM; Joshi JV; Donde UM; Sankoli GM; Virkar KD; Saxena BN
Contraception; 1985 Jan; 31(1):71-82. PubMed ID: 3921309
[TBL] [Abstract][Full Text] [Related]
11. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel.
Landgren BM; Johannisson E; Xing S; Aedo AR; Diczfalusy E
Contraception; 1985 Dec; 32(6):581-601. PubMed ID: 3937664
[TBL] [Abstract][Full Text] [Related]
12. Blood levels of levonorgestrel in women following vaginal placement of contraceptive pills.
Alvarez F; Faundes A; Johansson E; Coutinho E
Fertil Steril; 1983 Jul; 40(1):120-3. PubMed ID: 6407876
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate.
Landgren BM; Johannisson E; Masironi B; Diczfalusy E
Contraception; 1982 Dec; 26(6):567-85. PubMed ID: 6820337
[TBL] [Abstract][Full Text] [Related]
14. Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device.
Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T
Contraception; 1989 Feb; 39(2):195-204. PubMed ID: 2495893
[TBL] [Abstract][Full Text] [Related]
15. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
[TBL] [Abstract][Full Text] [Related]
16. Clinical and endocrinologic study of continuous levonorgestrel administration from subcutaneous solid polydimethylsiloxane rods.
Roy S; Stanczyk F; Mishell DR; Lumkin M; Gentzschein E
Contraception; 1980 Jun; 21(6):595-615. PubMed ID: 6775868
[TBL] [Abstract][Full Text] [Related]
17. Metabolic changes during treatment with two different progestogens.
Refn H; Kjaer A; Lebech AM; Borggaard B; Schierup L; Bremmelgaard A
Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):374-7. PubMed ID: 2115298
[TBL] [Abstract][Full Text] [Related]
18. The effect of a biodegradable contraceptive capsule (Capronor) containing levonorgestrel on gonadotropin, estrogen, and progesterone levels.
Ory SJ; Hammond CB; Yancy SG; Hendren RW; Pitt CG
Am J Obstet Gynecol; 1983 Mar; 145(5):600-5. PubMed ID: 6402933
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
Carlström K; Lunell NO; Zador G
Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
[TBL] [Abstract][Full Text] [Related]
20. Clinical chemistry in women treated with levonorgestrel implants (Norplant) or a TCu 200 IUD.
Croxatto HB; Diaz S; Robertson DN; Pavez M
Contraception; 1983 Mar; 27(3):281-8. PubMed ID: 6406139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]